MHSRS Award Winner: Broad-Spectrum Snakebite Antidote IPT (VIDEO)

OPMED (Operational Medical Systems)

Caption

The Broad-Spectrum Snakebite Antidote IPT and small-business partner, Ophirex Inc, accelerated the technical and programmatic maturity of the critical life-saving drug, varespladib, including two pivotal clinical trials in 4 years. The team mitigated manufacturing and clinical risks through early FDA engagement and capitalized on opportunities to accelerate schedule, utilizing SBIR contracting mechanisms; financial and acquisition planning; and stakeholder engagement. The team’s efforts will result in FDA-approval and fielding nearly 3 years ahead of schedule, providing an important capability for Warfighters deployed in far-forward, austere conditions where snakebites are a significant threat to life and limb.

Credit

Sara Barger, Defense Health Agency

Usage Restrictions

No restrictions.

License

Public Domain

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.